Clinical, Pathological, Hla Antigen and Immunological Evidence for Disease Heterogeneity in Myasthenia Gravis

D. A. S. Compston; Angela Vincent; John Newsom–Davis; J. R. Batchelor

doi:10.1093/brain/103.3.579

January 1, 1980Brain

Clinical, Pathological, Hla Antigen and Immunological Evidence for Disease Heterogeneity in Myasthenia Gravis

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate clinical, pathological, immunogenetic, and immunological characteristics to determine whether myasthenia gravis comprises distinct disease subgroups.
Assessed clinical features and thymic pathological findings in individuals diagnosed with myasthenia gravis.
Profiled human leukocyte antigen (HLA) frequencies and immunological markers to identify disease-associated patterns.
Identified clear variations in HLA antigen associations and immune profiles corresponding to different clinical presentations.
Demonstrated that myasthenia gravis is an immunologically and pathologically heterogeneous disorder rather than a single uniform disease entity.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis demonstrates distinct clinical, pathological, and HLA antigen profiles in myasthenia gravis, indicating biological heterogeneity across patient subgroups.

Abstract

D. A. S. Compston, A. Vincent, J. Newsom-Davis, J. R. Batchelor; Clinical, Pathological, Hla Antigen and Immunological Evidence for Disease Heterogeneity I

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Compston et al. (1980) studied this question.

synapsesocial.com/papers/6a742a66d084cc11716e8768 https://doi.org/10.1093/brain/103.3.579

View at Publisher

Ask AI

Bookmark

Share

Clinical, Pathological, Hla Antigen and Immunological Evidence for Disease Heterogeneity in Myasthenia Gravis

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Clinical, Pathological, Hla Antigen and Immunological Evidence for Disease Heterogeneity in Myasthenia Gravis

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading